All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Trial Watch-Immunostimulation with cytokines in cancer therapy

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323643" target="_blank" >RIV/00064203:_____/16:10323643 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/16:10323643

  • Result on the web

    <a href="http://dx.doi.org/10.1080/2162402X.2015.1115942" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1115942</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/2162402X.2015.1115942" target="_blank" >10.1080/2162402X.2015.1115942</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Trial Watch-Immunostimulation with cytokines in cancer therapy

  • Original language description

    During the past decade, great efforts have been dedicated to the development of clinically relevant interventions that would trigger potent (and hence potentially curative) anticancer immune responses. Indeed, developing neoplasms normally establish local and systemic immunosuppressive networks that inhibit tumor-targeting immune effector cells, be them natural or elicited by (immuno) therapy. One possible approach to boost anticancer immunity consists in the (generally systemic) administration of recombinant immunostimulatory cytokines. In a limited number of oncological indications, immunostimulatory cytokines mediate clinical activity as standalone immunotherapeutic interventions. Most often, however, immunostimulatory cytokines are employed as immunological adjuvants, i.e., to unleash the immunogenic potential of other immunotherapeutic agents, like tumor-targeting vaccines and checkpoint blockers. Here, we discuss recent preclinical and clinical advances in the use of some cytokines as immunostimulatory agents in oncological indications.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    EC - Immunology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    OncoImmunology [online]

  • ISSN

    2162-402X

  • e-ISSN

  • Volume of the periodical

    5

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    12

  • Pages from-to

  • UT code for WoS article

    000373385000045

  • EID of the result in the Scopus database

    2-s2.0-84959386440